ERBB2 and cancer: The DESTINY-PanTumor02 phase II trial included 267 pretreated patients with various HER2 expressions (from 0/unknown to 3+ score by IHC) in different cancer subtypes (biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, or other tumors) [22].